Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259146 | 0.97 | ALDH1A1 (0.32) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL8557919 | 0.90 | — | — | |
| SCHEMBL16572452 | 0.89 | ALDH1A1 (0.34) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL12703069 | 0.89 | MEN1 (0.46) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL9237706 | 0.89 | CA2 (0.40) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| Ethylene Glycol SCHEMBL27885940 | 0.88 | TSHR (0.33) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL749982 | 0.86 | CA1 (0.33) | ALDH1A1TP53HSD17B10CA2 | |
| SCHEMBL17453659 | 0.86 | TSHR (0.43) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL8780035 | 0.86 | CA2 (0.30) | CA2CA9 | |
| SCHEMBL8948892 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753578-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-10699916-B2 | Mold release film, process for its production, and process for producing semiconductor package | AGC Inc. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3082877-B1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-06-27 | — | — | US | disclosed |
| US-20180244717-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| US-10039807-B2 | bFGF-polymer conjugates, methods for making the same and applications thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-07 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| EP-3310813-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-20170207105-A1 | MOLD RELEASE FILM, PROCESS FOR ITS PRODUCTION, AND PROCESS FOR PRODUCING SEMICONDUCTOR PACKAGE | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-07-20 | — | — | US | disclosed |
| US-20170143795-A1 | bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-25 | — | — | US | disclosed |
| WO-2016203432-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| EP-3082877-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| US-20140335045-A1 | bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | NATIONAL SCIENCE FOUNDATION | 2014-11-13 | — | — | US | disclosed |
| EP-2138481-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY USING THE SAME | Ube Industries, Ltd. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ALDH1A1 3311/4885TP53 14/4885TSHR 2353/4885 |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CDH1, VIM | ALDH1A1 1376/4885TP53 101/4885TSHR 4722/4885 |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ALDH1A1 3311/4885TP53 14/4885TSHR 2353/4885 |
| US-10039807-B2 | bFGF-polymer conjugates, methods for making the same and applications thereof | FGF2, FGF1, FGFR1 | ALDH1A1 1396/4885TP53 861/4885TSHR 872/4885 |
| US-20140335045-A1 | bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | FGF2, FGF1, FGFR1 | ALDH1A1 1396/4885TP53 861/4885TSHR 872/4885 |
| US-20180244717-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | ALDH1A1 3311/4885TP53 14/4885TSHR 2353/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | ALDH1A1 3311/4885TP53 14/4885TSHR 2353/4885 |
| US-20170143795-A1 | bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | FGF2, FGF1, FGFR1 | ALDH1A1 1396/4885TP53 861/4885TSHR 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.